Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Q32 Bio
Biotech
Q32’s stock jumps 60% on latest phase 2 alopecia data
The phase 2 readout drew investor enthusiasm, supporting the biotech’s claim that the drug could offer a more durable alternative to JAK inhibitors.
James Waldron
Jul 13, 2026 10:40am
Akebia promises $12M for Q32’s rare kidney disease candidate
Dec 1, 2025 9:45pm
Incyte, FDA, Sun Pharma and more—Chutes & Ladders
Jun 27, 2025 8:30am
Q32 Bio sticks with bempikibart but lets go of staff
Feb 11, 2025 4:47am
Q32's stock plunges in wake of anti-IL-7R antibody's eczema fail
Dec 11, 2024 8:25am
J&J's medtech chief out the door—Chutes & Ladders
Oct 27, 2023 9:30am
